Faster drug discovery could hit ‘undruggable’ targets
A new technique has been developed which has the potential to harness bacteria to produce billions of different drug candidates to treat diseases like cancer.
List view / Grid view
A new technique has been developed which has the potential to harness bacteria to produce billions of different drug candidates to treat diseases like cancer.
Modelling technique that simultaneously evaluates the effects of possible protein mutations on protein-protein interactions implicated in disease, could cut pre-drug screening time, says research.
The G-protein coupled receptor Frizzled, implicated in diseases like cancer, can be targeted with small molecules which could provide the basis for anti-cancer therapeutics, according to researchers.
Researchers have discovered a new type of T-cell receptor that can kill most cancer types while leaving healthy cells unharmed.
Researchers have screened thousands of existing drug molecules against cancer cell lines to discover almost 50 compounds that combat the condition.
Studies have identified that the TPX2 protein recruits the molecular machinery required for the branching microtubule nucleation process, so could be a target for cancer therapies.
Research into the role of non-coding DNA in cancer development and progression has identified 30 regions that may contribute to tumour growth, which could be therapeutic targets.
Researchers have developed a novel metal-based fragment library of molecules that can be used to screen for new drug candidates.
A new study shows that the VISTA molecule stops the immune system responding to self-antigens, including those presented by cancer cells, so an anti-VISTA antibody could be a possible therapy.
Oncologic stem cells have been identified in many malignancies, and targeting these cells could help in the fight against cancer. Here are five of the most recent findings regarding cancer stem cells.
In a world first, researchers have grown immune cells from pluripotent stem cells in a dish, which could be used to develop immunotherapies or to test autoimmune disease treatments.
A study has demonstrated the success of new compounds that prevent FOXM1, a transcription factor, from increasing cancer proliferation.
A study has shown that the SVC112 molecule can prevent cancer stem cells from producing more tumour cells in cell lines and mice, with no impact on healthy cells.
Modern day oncology therapies have seen significant innovation in the last decade. It is high time we commit to using biomarkers that are driven by rational design and the latest computational methods.
A new study has revealed that the Siah2 protein is crucial to control Tregs in mice, which can reduce the effectiveness of immunotherapies.